У нас вы можете посмотреть бесплатно C-IP2 2022 Fall Conference - Panel 1: How Well Does the Antitrust Approach Fit the Biopharma Space? или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
Panelists: Lee Branstetter (Professor of Economics and Public Policy, Carnegie Mellon University Heinz College of Information Systems and Public Policy) Gregory Dolin (Associate Professor of Law, University of Baltimore School of Law; Scholar, Center for Intellectual Property x Innovation Policy) David Korn (Vice President, Intellectual Property and Law, PhRMA) Kevin D. McDonald (Partner, Jones Day) Moderator: Emily Michiko Morris (David L. Brennan Endowed Chair, Associate Professor, and Associate Director of the Center for Intellectual Property Law & Technology, University of Akron School of Law; Senior Fellow for Life Science and Scholar, Center for Intellectual Property x Innovation Policy) Many pharma-specific, sui generis legislative and regulatory regimes already exist, but many more have been proposed in the last couple of years in an effort to facilitate market entry of follow-on therapeutics. A few of these proposals would outright classify various practices using pharmaceutical patents and other exclusivities as antitrust violations. Almost all of the remaining proposals explicitly or implicitly rely on antitrust law and theory to support the idea that reining in patent and regulatory exclusivities are necessary to lower drug prices. The thought clearly underlying all of these proposals is that, absent these exclusivities, there would be increased “competition” within the pharmaceutical market. Thursday, September 22, 2022 George Mason University Mason Square, Arlington, VA https://cip2.gmu.edu/conferences-even...